Tumor suppressor gene alterations of spontaneously malignant transformed cells from human embryonic muscle in vitro

Oncology Reports

Volumn 24, Issue 2, 2010, Pages 555-561

  Wang, Xianyao ^a,b   Li, Wenyu ^a   Zheng, Jiakun ^a   Chen, Qiang ^a   Zou, Haiying ^c   Ma, Lian ^b   Lin, Guangyu ^b   Huang, Tianhua ^b   Huang, Ge ^b   Yang, Liye ^a,b  

^a Chaozhou Central Hospital Affiliated to Southern Medical University   (China)

^b SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^c HANSHAN NORMAL UNIVERSITY   (China)

Author keywords

9p21; p16; p21; p53; Sarcoma; Transformation; Tumor suppressor gene

Indexed keywords

5' METHYLTHIOADENOSINE PHOSPHORYLASE; PROTEIN P15; PROTEIN P16; PROTEIN P53; CYCLIN DEPENDENT KINASE INHIBITOR 2B;

ARTICLE; CELL TRANSFORMATION; CHROMOSOME 9P; CHROMOSOME ABERRATION; CHROMOSOME BAND; CONTROLLED STUDY; DNA SEQUENCE; EMBRYO; EXON; GENE DELETION; GENE INACTIVATION; GENE INSERTION; GENE SEQUENCE; HOMOZYGOSITY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; MALIGNANT TRANSFORMATION; MISSENSE MUTATION; MUSCLE CELL; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE; ANIMAL; ANIMAL EMBRYO; CHROMOSOME 9; EMBRYOLOGY; EMBRYONAL RHABDOMYOSARCOMA; FIBROSARCOMA; GENE EXPRESSION REGULATION; GENETICS; MESENCHYMAL STROMA CELL; METABOLISM; MOUSE; MUSCLE TUMOR; MUTATION; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; SKELETAL MUSCLE; TRANSFORMED CELL LINE;

ANIMALS; CELL LINE, TRANSFORMED; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 9; CYCLIN-DEPENDENT KINASE INHIBITOR P15; EMBRYO, MAMMALIAN; FIBROSARCOMA; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P16; GENES, TUMOR SUPPRESSOR; HUMANS; MESENCHYMAL STROMAL CELLS; MICE; MICE, NUDE; MUSCLE NEOPLASMS; MUSCLE, SKELETAL; MUTATION; RHABDOMYOSARCOMA, EMBRYONAL;

EID: 77954377818     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000892     Document Type: Article

References (42)

1. Huang PS and Heimbrook DC: Oncogene products as therapeutic targets for cancer. Curr Opin Oncol 9: 94-100, 1997.
2. Schinzel AC and Hahn WC: Oncogenic transformation and experimental models of human cancer. Front Biosci 13: 71-84, 2008.
3. Skapek SX, Pan YR and Lee EY: Regulation of cell lineage specification by the retinoblastoma tumor suppressor. Oncogene 25: 5268-5276, 2006.
4. Li Y, Nichols MA, Shay JW and Xiong Y: Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer Res 54: 6078-6082, 1994. (Pubitemid 24378633)
5. Bourdon JC: p53 and its isoforms in cancer. Br J Cancer 97: 277-282, 2007.
6. Rubio D, Garcia S, Paz MF, De la Cueva T, Lopez- Fernandez LA, Lloyd AC, Garcia-Castro J and Bernad A: Molecular characterization of spontaneous mesenchymal stem cell transformation. PLoS ONE 3: e1398, 2008.
7. Xu W, Qian H, Zhu W, Chen Y, Shao Q, Sun X, Hu J, Han C and Zhang X: A novel tumor cell line cloned from mutated human embryonic bone marrow mesenchymal stem cells. Oncol Rep 12: 501-508, 2004.
8. Rubio D, Garcia-Castro J, Martín MC, de la Fuente R, Cigudosa JC, Lloyd AC and Bernad A: Spontaneous human adult stem cell transformation. Cancer Res 65: 3035-3039, 2005.
9. Gibbs CP, Kukekov VG, Reith JD, Tchigrinova O, Suslov ON, Scott EW, Ghivizzani SC, Ignatova TN and Steindler DA: Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia 7: 967-976, 2005.
10. Yang L, Chen Q, Zhang S, Wang X, Li W, Wen J, Huang X, Zheng J, Huang G, Huang T and Ju G: A novel mutated cell line with characteristics of dedifferentiated chondrosarcoma. Int J Mol Med 24: 427-435, 2009.
11. Nagahashi M, Ajioka Y, Lang I, Szentirmay Z, Kasler M, Nakadaira H, Yokoyama N, Watanabe G, Nishikura K, Wakai T, Shirai Y, Hatakeyama K and Yamamoto M: Genetic changes of p53, K-ras, and microsatellite instability in gallbladder carcinoma in high-incidence areas of Japan and Hungary. World J Gastroenterol 14: 70-75, 2008.
12. Bernardo ME, Zaffaroni N, Novara F, Cometa AM, Avanzini MA, Moretta A, Montagna D, Maccario R, Villa R, Daidone MG, Zuffardi O and Locatelli F: Human bone marrow derived mesenchymal stem cells do not undergo transformation after longterm in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res 67: 9142-9149, 2007.
13. Riggi N, Cironi L, Provero P, Suvà ML, Kaloulis K, Garcia- Echeverria C, Hoffmann F, Trumpp A and Stamenkovic I: Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells. Cancer Res 65: 11459-11468, 2005.
14. Todaro GJ and Green H: Quantitative studies of the growth of mouse embryo cells in culture and their development into established lines. Cell Biol 17: 299-313, 1963.
15. Meek RL, Bowman PD and Daniel CW: Establishment of rat embryonic cells in vitro. Relationship of DNA synthesis, senescence, and acquisition of unlimited growth potential. Exp Cell Res 127: 127-132, 1980.
16. Curatolo L, Erba E and Morasca L: Culture conditions induce the appearance of immortalized C3H mouse cell lines. In Vitro 20: 597-601, 1984.
17. Harvey DM and Levine AJ: p53 alteration is a common event in the spontaneous immortalization of primary BALB/c murine embryo fibroblasts. Genes Dev 5: 2375-2385, 1991.
18. Miura M, Miura Y, Padilla-Nash HM, Molinolo AA, Fu B, Patel V, Seo BM, Sonoyama W, Zheng JJ, Baker CC, Chen W, Ried T and Shi S: Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation. Stem Cells 24: 1095-1103, 2006.
19. Aguilar S, Nye E, Chan J, Loebinger M, Spencer-Dene B, Fisk N, Stamp G, Bonnet D and Janes SM: Murine but not human mesenchymal stem cells generate osteosarcoma-like lesions in the lung. Stem Cells 25: 1586-1594, 2007.
20. Tolar J, Nauta AJ, Osborn MJ, Panoskaltsis Mortari A, McElmurry RT, Bell S, Xia L, Zhou N, Riddle M, Schroeder TM, Westendorf JJ, McIvor RS, Hogendoorn PC, Szuhai K, Oseth L, Hirsch B, Yant SR, Kay MA, Peister A, Prockop DJ, Fibbe WE and Blazar BR: Sarcoma derived from cultured mesenchymal stem cells. Stem Cells 25: 371-379, 2007.
21. Fujii H, Honoki K, Tsujiuchi T, Kido A, Yoshitani K, Mori T and Takakura Y: Reduced expression of INK4a/ARF genes in stem-like sphere cells from rat sarcomas. Biochem Biophys Res Commun 362: 773-778, 2007.
22. Olopade OI, Buchhagen DL, Malik K, Sherman J, Nobori T, Bader S, Nau MM, Gazdar AF, Minna JD and Diaz MO: Homozygous loss of the interferon genes defines the critical region on 9p that is deleted in lung cancers. Cancer Res 53: 2410-2415, 1993.
23. Cheng JQ, Jhanwar SC, Lu YY and Testa JR: Homozygous deletions within 9p21-p22 identify a small critical region of chromosomal loss in human malignant mesotheliomas. Cancer Res 53: 4761-4763, 1993.
24. Stadler WM and Olopade OI: The 9p21 region in bladder cancer cell lines: large homozygous deletion inactivate the CDKN2, CDKN2B and MTAP genes. Urol Res 24: 239-244, 1996.
25. Worsham MJ, Chen KM, Tiwari N, Pals G, Schouten JP, Sethi S and Benninger MS: Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 132: 409-415, 2006.
26. Knudsen ES and Knudsen KE: Retinoblastoma tumor suppressor: where cancer meets the cell cycle. Exp Biol Med 231: 1271-1281, 2006.
27. Kovar H, Jug G, Aryee DN, Zoubek A, Ambros P, Gruber B, Windhager R and Gadner H: Among genes involved in the RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is frequently lost in the Ewing family of tumors. Oncogene 15: 2225-2232, 1997.
28. Nobori T, Takabayashi K, Tran P, Orvis L, Batova A, Yu AL and Carson DA: Genomic cloning of methylthioadenosine phosphorylase: a purine metabolic enzyme deficient in multiple different cancers. Proc Natl Acad Sci USA 93: 6203-6208, 1996. (Pubitemid 26190828)
29. Christopher SA, Diegelman P, Porter CW and Kruger WD: Methylthioadenosine phosphorylase, a gene frequently codeleted with p16(cdkN2a/ARF), acts as a tumor suppressor in a breast cancer cell line. Cancer Res 62: 6639-6644, 2002. (Pubitemid 35364132)
30. Schmid M, Malicki D, Nobori T, Rosenbach MD, Campbell K, Carson DA and Carrera CJ: Homozygous deletions of methylthioadenosine phosphorylase (MTAP) are more frequent than p16INK4A (CDKN2) homozygous deletions in primary nonsmall cell lung cancers (NSCLC). Oncogene 17: 2669-2675, 1998.
31. García-Castellano JM, Villanueva A, Healey JH, Sowers R, Cordon-Cardo C, Huvos A, Bertino JR, Meyers P and Gorlick R: Methylthioadenosine phosphorylase gene deletions are common in osteosarcoma. Clin Cancer Res 8: 782-787, 2002. (Pubitemid 34742108)
32. Hussain SP and Harris CC: Molecular epidemiology of human cancer: contribution of mutation spectra studies of tumor suppressor genes. Cancer Res 58: 4023-4037, 1998.
33. Beroud C and Soussi T: p53 gene mutation: software and database. Nucleic Acids Res 26: 200-204, 1998.
34. Cariello NF, Beroud C and Soussi T: Database and software for the analysis of mutations at the human p53 gene. Cancer Res 54: 4454-4460, 1994.
35. Hainaut P, Hernandez T, Robinson A, Rodriguez-Tome P, Flores T, Hollstein M, Harris CC and Montesano R: IARC database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools. Nucleic Acids Res 26: 205-213, 1998.
36. Hamroun D, Kato S, Ishioka C, Claustres M, Béroud C and Soussi T: The UMD TP53 database and website: update and revisions. Hum Mutat 27: 14-20, 2006.
37. Liu Y and Bodmer WF: Analysis of p53 mutations and their expression in 56 colorectal cancer cell lines. Proc Natl Acad Sci USA 103: 976-981, 2006.
38. Nigro JM, Baker SJ, Preisinger AC, et al: Mutations in the p53 gene occur in diverse human tumour types. Nature 342: 705-708, 1989.
39. Albor A, Flessate DM, Soussi T and Notario V: 3-Methylcholanthrene inactivates the p53 gene in syrian hamster embryo fibroblasts by inducing a specific intronic point mutation. Cancer Res 54: 4502-4507, 1994.
40. Das P, Kotilingam D, Korchin B, Liu J, Yu D, Lazar AJ, Pollock RE and Lev D: High prevalence of p53 exon 4 mutations in soft tissue sarcoma. Cancer 109: 2323-2333, 2007.
41. Cordon-Cardo C, Latres E, Drobnjak M, Oliva MR, Pollack D, Woodruff JM, Marechal V, Chen J, Brennan MF and Levine AJ: Chromosome 17 abnormalities and TP53 mutations in adult soft tissue sarcomas. Am J Pathol 145: 345-355, 1994.
42. Li H, Fan X, Kovi RC, Jo Y, Moquin B, Konz R, Stoicov C, Kurt-Jones E, Grossman SR, Lyle S, Rogers AB, Montrose M and Houghton J: Spontaneous expression of embryonic factors and p53 point mutations in aged mesenchymal stem cells: a model of age-related tumorigenesis in mice. Cancer Res 67: 10889-10898, 2007.